Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China…
$25.48+12.74%
报价 2026-11-06
市值
$2.87B
EV
$2.55B
PE (TTM)
–
预期 PE
–
52 周区间距高点 -5.6%
$16.30$27.00
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ZLABZai Lab Limited | $2.87B | +12.7% | – | 56.5% | – | – | – | |
| IRONDisc Medicine, Inc. | $3.03B | +0.6% | -47.5% | 0% | – | – | – | |
| IDYAIDEAYA Biosciences, Inc. | $3.01B | +1.9% | -84.0% | 99.5% | – | – | – | |
| ADMAADMA Biologics, Inc. | $2.85B | -3.6% | +11.7% | 68.5% | 16.7x | 12.0x | 22.3x | |
| VCELVericel Corporation | $2.8B | +5.5% | +21.1% | 74.5% | 82.8x | 56.7x | 61.0x | |
| XERSXeris Biopharma Holdings, Inc. | $2.77B | +16.2% | +34.6% | 84.4% | – | 109.0x | 38.2x | |
| BEAMBeam Therapeutics Inc. | $2.73B | +2.1% | +81.1% | 100% | – | – | – | |
| XNCRXencor, Inc. | $2.66B | +5.0% | +15.5% | 93.9% | – | – | – | |
| RCUSArcus Biosciences, Inc. | $2.59B | +3.3% | -70.3% | 97% | – | – | – | |
| 同行中位数 | – | – | +13.6% | 89.2% | 49.7x | 56.7x | 38.2x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。
研究材料
电话会纪要摘要
暂无纪要摘要。